FinancialContent

ABIOMED, Inc. - Common Stock (NQ:ABMD)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 21, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ABIOMED, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Risk Vs Reward Vs Folly: Navigating Investment Choices ↗
During the dot-com era, many individuals ridiculed Buffett for his refusal to invest in ventures that contradicted his principles. Years later, the majority of these so-called experts, if not all of... 
Via Talk Markets
News headline image
Is It Too Late to Buy Johnson & Johnson's Stock? ↗
This healthcare juggernaut's recent quarterly results prove just how strong its business is. 
Via The Motley Fool
News headline image
2 Best Buffett Stocks to Buy for the Long Haul ↗
Both of these stocks look like bargains right now. 
Via The Motley Fool
News headline image
FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
From Abiomed, Inc.
Via Business Wire
If You Invested $100 In This Stock 10 Years Ago, You Would Have $2,800 Today ↗
 
Via Benzinga
Here's How Much You Would Have Made Owning Abiomed Stock In The Last 15 Years ↗
 
Via Benzinga
Will Investors Notice Exciting Sign On Abiomed's Chart? ↗
 
Via Benzinga
News headline image
Interest Rate Hikes Won't Stop These 2 Cash-Rich Growth Stocks ↗
Even if interest rates go up, you likely won't need to worry about these stocks. 
Via The Motley Fool
News headline image
The Best Stocks to Invest $20,000 in Right Now ↗
The investments you make now could power your portfolio returns for years to come. 
Via The Motley Fool
News headline image
Warren Buffett Loves These Stocks. Should You Buy Them Before 2023? ↗
There's a lot more ahead for these market giants. 
Via The Motley Fool
News headline image
Pfizer, Novartis Are Among Overbought Healthcare Stocks: Are They Worth A Look? ↗
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. Here’s the latest list of major overbought players in this sector, with an RSI... 
Via Benzinga
News headline image
2 Top Dividend Kings to Buy for the Long Haul ↗
No matter how much changes, these two healthcare giants keep performing. 
Via The Motley Fool
News headline image
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months. 
Via MarketBeat
News headline image
This Monster Dividend Stock Isn't Done Growing ↗
Is another deal on the way for Johnson & Johnson? 
Via The Motley Fool
News headline image
Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi ↗
There are now two companies in the ring for a Horizon takeover. 
Via Investor's Business Daily
News headline image
First Patients in the World Treated with Impella RP Flex with SmartAssist
From Abiomed, Inc.
Via Business Wire
News headline image
3 Healthcare Stocks to Buy and Hold for the Next 10 Years ↗
This space is ripe with opportunities for investors. 
Via The Motley Fool
News headline image
Analyst Forecasts $101-117/Share Offer Price For Horizon Therapeutics' Buyout ↗
 
Via Benzinga
News headline image
Bear Market Blues? 3 of the Best Stocks to Own in 2023 ↗
2023 could be a big year for each of these healthcare companies. 
Via The Motley Fool
News headline image
Peering Into Abiomed's Recent Short Interest ↗
Abiomed's (NASDAQ:ABMD) short percent of float has risen 6.62% since its last report. The company recently reported that it has 2.08 million shares sold short, which is 5.96% of all regular shares that... 
Via Benzinga
News headline image
ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
S&P 500 Component DexCom Set For Further Price, Earnings Growth
Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023. 
Via MarketBeat
Topics Stocks
News headline image
2 Warren Buffett Passive Income Stocks You Can Buy to Boost Your Yield ↗
Buffett loves stocks that pay dividends. Is it any wonder Berkshire Hathaway is poised to collect more than $6 billion worth of them next year? 
Via The Motley Fool
News headline image
Better Buy: Johnson & Johnson vs. Abbott Laboratories ↗
These two healthcare giants are among the safest stocks investors can buy right now. 
Via The Motley Fool
News headline image
Johnson & Johnson Could Level Up With Its $16.8 Billion Purchase of Abiomed ↗
The company is planting seeds for future growth. 
Via The Motley Fool
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
2 Healthcare Stocks You Can Buy and Hold for the Next Decade ↗
These robust businesses will be around well beyond the next 10 years. 
Via The Motley Fool
News headline image
3 No-Brainer Stocks to Buy in a Downturn ↗
These companies thrive when others falter. 
Via The Motley Fool
News headline image
Johnson & Johnson's Big Purchase, Amazon's New Moves, and More ↗
Plus, we run through some shortcuts that could help you with your financial planning. 
Via The Motley Fool
News headline image
Is Johnson & Johnson's Purchase of Abiomed Good for Investors? ↗
The $16.6 billion acquisition shakes up MedTech. 
Via The Motley Fool
< Previous 1 2 3 4 5 Next >